Esta página foi traduzida automaticamente e a precisão da tradução não é garantida. Por favor, consulte o versão em inglês para um texto fonte.

Avaliando a entrega e os efeitos dos líquidos de vaporização de THC na corrente sanguínea

10 de novembro de 2026 atualizado por: Roswell Park Cancer Institute

Acute Effects of Sequential Nicotine Vaping on the Pharmacokinetic and Pharmacodynamic Properties of Vaped THC: A Randomized Within-Subject Crossover Study

This clinical trial assesses differences in the delivery of THC to the bloodstream depending on whether nicotine vapes are used before or after THC. While there has been much recent publicity about vaping products and concern about their safety considering their increasing use for THC administration, the THC delivery profile associated with THC liquid vaping products in human subjects is currently unknown. Importantly, how the delivery to the bloodstream of THC vaping liquids compare to delivery from smoked cannabis, which is the most used method of cannabis delivery, will serve as an important benchmark for evaluating the delivery and effects of THC vaping products, and their relative safety.

Visão geral do estudo

Descrição detalhada

PRIMARY OBJECTIVES:

I. Assess pharmacokinetic (PK)/pharmacodynamic (PD) profiles of THC vaping liquids administered with co-use of vaped nicotine.

II. Outcomes of interest will be assessed overall, and according to biological sex.

SECONDARY OBJECTIVES:

I. Safety. II. Assessment of differences in puffing behaviors. III. Short-term subjective drug effects, and cognitive performance following THC use without nicotine versus (vs.) THC use with pre-nicotine use vs. THC use with post-nicotine use in current consumers of both vaped cannabis and vaped nicotine products.

OUTLINE: Participants are randomized to 1 of 3 arms.

ARM A: Participants complete 3 vaping sessions separated by 7-14 days on study:

  • VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.
  • VISIT 2: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.
  • VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.

ARM B: Participants complete 3 vaping sessions separated by 7-14 days on study:

  • VISIT 1: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.
  • VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.
  • VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.

ARM C: Participants complete 3 vaping sessions separated by 7-14 days on study:

  • VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.
  • VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.
  • VISIT 3: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.

All participants also undergo blood sample collection throughout the trial.

After completion of study intervention, participants are followed up at 30 days.

Tipo de estudo

Intervencional

Inscrição (Estimado)

60

Estágio

  • Fase inicial 1

Contactos e Locais

Esta seção fornece os detalhes de contato para aqueles que conduzem o estudo e informações sobre onde este estudo está sendo realizado.

Locais de estudo

    • New York
      • Buffalo, New York, Estados Unidos, 14263
        • Roswell Park Cancer Institute
        • Contato:
        • Investigador principal:
          • Danielle M. Smith

Critérios de participação

Os pesquisadores procuram pessoas que se encaixem em uma determinada descrição, chamada de critérios de elegibilidade. Alguns exemplos desses critérios são a condição geral de saúde de uma pessoa ou tratamentos anteriores.

Critérios de elegibilidade

Idades elegíveis para estudo

21 anos e mais velhos (Adulto, Adulto mais velho)

Aceita Voluntários Saudáveis

Sim

Gêneros Elegíveis para o Estudo

Tudo

Descrição

Inclusion Criteria:

  • Age ≥ 21 years of age; (self-reported on screening, verified at study visit).
  • Report use of commercial THC vaping cartridges for at least 3 months prior to enrollment; (self-reported).
  • Experience with THC potency at or above the study product AND experience with chasing THC with nicotine (at least monthly); (self-reported).
  • Report use of THC vaping liquids at least weekly (4x/month); (self-reported).
  • Daily use of nicotine vaping products containing >2% nicotine (>20mg/ml for at least 3 months prior to enrollment; (self-reported).
  • Report of not currently trying to become pregnant (females). Women of childbearing potential must be willing to provide a urine sample and test negative prior to receiving any study-related products/procedures.
  • Willing to complete a THC saliva test to check for recent use (NarcoCheck Ref#: NCE-STHC-1), semi-quantitative urinary THCA rapid test (NarcoCheck® THC Pre Dosage), and an illicit drug urine test (NarcoCheck® Évolutive®) during baseline testing, prior to receiving any study-related products.
  • Willing to abstain from nicotine use for 8 hours prior to each study session and abstain from cannabis use 1 day prior to each session.
  • Participant must understand the investigational nature of this study and sign an Institutional Review Board approved written informed consent form prior to receiving any study related procedure.

Exclusion Criteria:

  • Unwilling or unable to follow protocol abstinence requirements based on more than two instances of a positive THC saliva test (NarcoCheck Ref#:NCE-S THC-1).

  • Illegal or non-prescription drug use within the past 90 days. As detected by NarcoCheck® Évolutive® (detection in human urine of the 12 most currently abused drugs) at the first session and prior to receiving any study product. THC use detected by NarcoCheck® Évolutive® is permitted

  • Illegal or non-prescription drug use/alcohol substance use disorder (SUD) within the past year; (self-reported).

  • Report drinking alcohol more than 3x per week with 5 or more drinks per occasions (males) or with 4 or more drinks per occasion; (women).

  • Report of daily cigarette use; (self-reported).

  • Current or prior diagnosis of schizophrenia, bipolar disorder, or other severe psychotic mental illness; (self-reported).

  • Current or prior diagnosis of myocardial infarction, arrhythmia, or congestive heart failure (self-reported)

  • Current or prior diagnosis of chronic obstructive pulmonary disorder (COPD), cystic fibrosis, pulmonary hypertension, pulmonary edema, pulmonary embolus, or other uncontrolled respiratory conditions

  • Current cancer diagnosis.

  • Pregnant, currently trying to become pregnant, or breastfeeding (females); (self-reported; pregnancy validated on study visit by urine test).

  • Regular use of medications that contain nicotine, induce CYP2A6, stimulants, or sympatholytics (e.g., beta-blockers); (self-reported).

  • Unwilling or unable to follow protocol requirements.

  • Any condition which in the Investigator's opinion deems the participant an unsuitable candidate for participation.

  • The following special populations will be excluded:

    • Cognitively impaired adults/adults with impaired decision-making capacity
    • Individuals who are not yet adults (infants, children, teenagers)
    • Pregnant women
    • Prisoners
  • No children or person under the age of 21 will be involved in the study. While those under 21 may use cannabis smoked or vaping products, the legal age of purchasing and using those products in New York State is 21. The current legal age to purchase and use tobacco products in New York State (NYS) is 21. Thus, our provision of study product to adults aged 21 and older is in line with current NYS law.

Plano de estudo

Esta seção fornece detalhes do plano de estudo, incluindo como o estudo é projetado e o que o estudo está medindo.

Como o estudo é projetado?

Detalhes do projeto

  • Finalidade Principal: Ciência básica
  • Alocação: Randomizado
  • Modelo Intervencional: Atribuição cruzada
  • Mascaramento: Quadruplicar

Armas e Intervenções

Grupo de Participantes / Braço
Intervenção / Tratamento
Experimental: Arm A (placebo, THC, nicotine)

Participants complete 3 vaping sessions separated by 7-14 days on study:

  • VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.
  • VISIT 2: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.
  • VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.

All participants also undergo blood sample collection throughout the trial.

Ancillary studies

Undergo blood collection

Outros nomes:
  • Coleta de Amostras Biológicas
  • Bioespécime coletado
  • Coleta de amostras

Vape THC

Outros nomes:
  • Cannabis sativa
  • Topo de Floração de Cannabis sativa
  • Cannabis sativa Subsp. Extrato de Floração Superior
  • Cannabis sativa Topo

Vape active nicotine

Outros nomes:
  • (-)-Nicotina
  • Placa de rede

Vape placebo nicotine

Experimental: Arm B (placebo, THC, nicotine)

Participants complete 3 vaping sessions separated by 7-14 days on study:

  • VISIT 1: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.
  • VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.
  • VISIT 3: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.

All participants also undergo blood sample collection throughout the trial.

Ancillary studies

Undergo blood collection

Outros nomes:
  • Coleta de Amostras Biológicas
  • Bioespécime coletado
  • Coleta de amostras

Vape THC

Outros nomes:
  • Cannabis sativa
  • Topo de Floração de Cannabis sativa
  • Cannabis sativa Subsp. Extrato de Floração Superior
  • Cannabis sativa Topo

Vape active nicotine

Outros nomes:
  • (-)-Nicotina
  • Placa de rede

Vape placebo nicotine

Experimental: Arm C (placebo, THC, nicotine)

Participants complete 3 vaping sessions separated by 7-14 days on study:

  • VISIT 1: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then nicotine for 10 minutes.
  • VISIT 2: Participants vape placebo nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine again for 10 minutes.
  • VISIT 3: Participants vape nicotine for 10 minutes, followed by THC for 10 minutes, and then placebo nicotine for 10 minutes.

All participants also undergo blood sample collection throughout the trial.

Ancillary studies

Undergo blood collection

Outros nomes:
  • Coleta de Amostras Biológicas
  • Bioespécime coletado
  • Coleta de amostras

Vape THC

Outros nomes:
  • Cannabis sativa
  • Topo de Floração de Cannabis sativa
  • Cannabis sativa Subsp. Extrato de Floração Superior
  • Cannabis sativa Topo

Vape active nicotine

Outros nomes:
  • (-)-Nicotina
  • Placa de rede

Vape placebo nicotine

O que o estudo está medindo?

Medidas de resultados primários

Medida de resultado
Descrição da medida
Prazo
Maximum concentration of THC in plasma (Cmax)
Prazo: Up to 21 days

Pharmacokinetics (PK) profiles of THC in plasma will be determined using a visual plot of plasma THC concentrations by time. Parameters will be derived using non-compartmental analysis in Phoenix WinNonlin and adjusted for baseline THC levels. Will be summarized by nicotine status using the appropriate descriptive statistics and graphical summaries.

Up to 21 days
Time to maximum concentration of THC in plasma (Tmax)
Prazo: Up to 21 days

Blood samples will be collected for plasma levels of THC. Parameters will be derived using linear mixed models.

Up to 21 days
Area under the plasma concentration-time curve from 0-120 minutes (AUC0-120)
Prazo: Up to 21 days

Blood samples will be collected for plasma levels of THC. Parameters will be derived using linear mixed models

Up to 21 days

Medidas de resultados secundários

Medida de resultado
Descrição da medida
Prazo
Incidence of adverse events (AEs)
Prazo: Up to 30 days after completion of study intervention

AEs will be summarized by nicotine condition and grade using frequencies and relative frequencies. Common Terminology Criteria for Adverse Events (CTCAE) version 5.0 will be utilized for AE reporting.

Up to 30 days after completion of study intervention
Puffing behaviors
Prazo: Up to 21 days

puff duration

Up to 21 days
Puffing behaviors
Prazo: Up to 21 days

puff number

Up to 21 days
Short-term drug effects
Prazo: Up to 21 days

The short-term drug effects (Drug Effects Questionnaire [DEQ), The DEQ rates sixteen component items using a visual analog scale (0-100) to examine drug effects pre- and post-use

Up to 21 days
Marijuana Withdrawal Checklist [MWC)
Prazo: Up to 21 days

The Marijuana Withdrawal Questionnaire Total Score includes items assessing anxiety, depression, irritability, appetite, aggression/anger, sleep disturbance, somatic disturbances, and craving to use marijuana. The potential range of this total score is from "0" = no withdrawal symptoms to "47" = maximally high levels of withdrawal

Up to 21 days
Digit Symbol Substitution Task (DSST)
Prazo: Up to 21 days

An assessment of cognitive dysfunction that test ability to complete daily tasks

Up to 21 days
Paced Auditory Serial Addition Task (PASET)
Prazo: Up to 21 days

Measures of working memory and concentration .

Up to 21 days
Tobacco Craving Questionnaire (Short Form)
Prazo: Up to 21 days

Self reported 47-item questionnaire that assesses tobacco craving. Items are rated on a Likert-type scale from 1 (strongly disagree) to 7 (strongly agree). Factor scores for each participant are obtained by summing the three items in each factor scale, yielding a score ranging from 3 to 21.

Up to 21 days

Colaboradores e Investigadores

É aqui que você encontrará pessoas e organizações envolvidas com este estudo.

Investigadores

  • Investigador principal: Danielle M Smith, Roswell Park Cancer Institute

Datas de registro do estudo

Essas datas acompanham o progresso do registro do estudo e os envios de resumo dos resultados para ClinicalTrials.gov. Os registros do estudo e os resultados relatados são revisados ​​pela National Library of Medicine (NLM) para garantir que atendam aos padrões específicos de controle de qualidade antes de serem publicados no site público.

Datas Principais do Estudo

Início do estudo (Estimado)

15 de dezembro de 2026

Conclusão Primária (Estimado)

1 de dezembro de 2028

Conclusão do estudo (Estimado)

1 de dezembro de 2029

Datas de inscrição no estudo

Enviado pela primeira vez

7 de março de 2024

Enviado pela primeira vez que atendeu aos critérios de CQ

20 de março de 2024

Primeira postagem (Real)

27 de março de 2024

Atualizações de registro de estudo

Última Atualização Postada (Real)

16 de novembro de 2026

Última atualização enviada que atendeu aos critérios de controle de qualidade

10 de novembro de 2026

Última verificação

1 de novembro de 2026

Mais Informações

Termos relacionados a este estudo

Outros números de identificação do estudo

  • I-3597023
  • R01DA057228 (Concessão/Contrato do NIH dos EUA)
  • I-3597023 (Outro identificador: Roswell Park Cancer Institute)
  • NCI-2024-01556 (Identificador de registro: CTRP (Clinical Trial Reporting Program))

Informações sobre medicamentos e dispositivos, documentos de estudo

Estuda um medicamento regulamentado pela FDA dos EUA

Sim

Estuda um produto de dispositivo regulamentado pela FDA dos EUA

Não

produto fabricado e exportado dos EUA

Sim

Essas informações foram obtidas diretamente do site clinicaltrials.gov sem nenhuma alteração. Se você tiver alguma solicitação para alterar, remover ou atualizar os detalhes do seu estudo, entre em contato com register@clinicaltrials.gov. Assim que uma alteração for implementada em clinicaltrials.gov, ela também será atualizada automaticamente em nosso site .

Se inscrever